Trending...
- California: Governor Newsom announces appointments 9.10.25 - 340
- John Thomas calls for unity and prayer after tragic loss - 311
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 303
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21st Annual Pain Therapeutics Conference. The conference takes place virtually May 10-11th. Presentations will be available for registered attendees via the conference website.
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018, Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com.
More on The Californer
SOURCE Neurana Pharmaceuticals, Inc.
Related Links
http://www.neuranapharma.com
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana's lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018, Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com.
More on The Californer
- Descryber Launches Innovative Web App to Simplify DIY Trademark Applications
- LVN Jobs in LA Connects Licensed Vocational Nurses with Top LVN Staffing Jobs in Los Angeles
- California-based productions win big at Emmy Awards
- White Glove Restoration Expands 24/7 Emergency Response Team Across San Diego County
- Marin's Rising Star Easton Cain Revives American Regionalism in the Bay Area
SOURCE Neurana Pharmaceuticals, Inc.
Related Links
http://www.neuranapharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- Governor Newsom announces appointments, including new California Air Resources Board Chair
- Legendary Mitchell-Hedges Crystal Skull Arrives in Beverly Hills
- NEW power supply release from Kepco Dynatronix - HSP Advanced
- St. Augustine Honors Hispanic Heritage Month
- WesternU researchers show Osteopathic Manipulative Treatment improves efficacy of COVID-19 vaccine
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Machine Vision Products Unveils New Homepage at Visionpro.com
- Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences
- California: Governor Newsom proclaims Latino Heritage Month
- MEDIA ALERT: Cisco's WebexOne Event Spotlights Global AI Brands and Ryan Reynolds, Acclaimed Actor, Film Producer, and Entrepreneur
- Patrick Perez Steps Beyond Crunchyroll to Shape the Next Wave of Streaming & Media Innovation
- Mesa West Capital Originates $43.5 Million Loan to Refi LA Area Apartment Community
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Pacsun Announces Industry First Pacsun Youth Advisory Council: Empowering Its Consumers as Co-Creators in Brand Strategy
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance